laboratori corpor america
think lh outperform market follow
print thank strong outlook covanc key
metric ttm book-to-bil quit strong outlook
mid-to-high singl digit organ revenu growth seem
readili achiev progress covanc cost save
invigor program could also increment posit
invest thesi hing strong covanc perform
larg view posit rais estim price target
quick take quarter lh report in-lin revenu
ep beat driven strong margin line item
diagnost busi fundament trend continu strong
organ volum revenu per requisit
women health drug
monitor oncology/genet echo trend seen
estim covanc book-to-bil would solid
quarterli basi organ constant currenc revenu
growth experienc second consecut quarter acceler
set good detail see varianc tabl
guidanc hard compar guidanc consensu sinc
analyst reset number
half done tax reform get sens revenu
comparison compar growth rate compar favor
consensu segment consolid basi
revenu growth compar favor consensu though
probabl includ larger fx benefit analyst model
ep also compar favor consensu
includ benefit tax reform detail see guidanc
tabl exhibit
read-through biggest read-through contract
research cro space yet seen pure-play
compani report read-through labcorp covanc
busi posit view compani like iclr
covanc book continu strong
think mostli function macro pictur also
concern debat implement messag
big deal expect accord file
covanc compani formal restat
number restat new account rule oper incom
would higherimmateri grand scheme
certainli neg analyst fear
compani data secur llc estim reuter
exclud amort intang restructur non-recur item
compani prioriti stock list
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
report date estactualconsyr cost gener administr pre-tax incom incom net share analysisyr yrseqgross bpssg bpsebitda bpsoper bpspretax bpstax bpsnet bpsrevenu analysisyr yrseqlabcorp diagnost bp price bpsgrowth bpsgrowth bpsorgan bpsacquisit bpstotal bpsrevenu per bpsoper oper bpscovanc drug develop bpsgrowth bpsgrowth bpsgrowth bpsbegin net net acquir backlog/fx end net oper bpstotal growth bpstotal growth bpstotal growth bpsgrowth bpsunalloc corpor oper oper bpssourc compani data factset secur llc estimatesin mm except epsactualfi end laboratori corpor america
priorcurrentchangepriorcurrentchangetot cost gener administr pre-tax incom incom net share analysisgross bpssg bpsebitda bpsoper bpspretax bpstax bpsnet bpssegment analysislabcorp diagnost bp price bpsgrowth bpsgrowth bpsgrowth bpsgrowth bpsoper bpscovanc drug develop bpsgrowth bpsgrowth bpsgrowth bpsbegin net net acquir backlog/fx adjustments- end bpsoper bpstotal growth bpstotal growth bpstotal growth bpsgrowth bpsunalloc corpor oper bpssourc compani data secur llc estimatesfi end mm except life scienc tool servic diagnost
revenu growth fxlabcorp revenu growth fxcovanc revenu growth fxadjust pama revfcf compani data secur llccovanc launchpad target save cost total laboratori corpor america
labcorp incom statement fy end total cost gross sell gener administr oper interest pre-tax provis incom net incom minor net non-gaap dilut share margin analysisgross analysi y/i total share diagnost price per oper drug develop growth net net acquir backlog/fx end net oper total growth growth growth corpor oper oper data total net cash debt ttm debt ttm flow capit free cash free cash flow per invest normal per sourc compani data secur llc estimatesin million except epsnon-gaap incom statementrevenu analysi life scienc tool servic diagnost
price target
price target dcf-base wacc termin noplat growth repres
ep estim risk includ slow expens consolid lab industri price volum
headwind demand contract research servic could deterior pharma compani come
pressur due drug price consolid fund challeng disrupt demand
labcorp taken strategi diversifi away structur challeng clinic lab space
attract pharma servic space one third revenu come pharma
custom labcorp rel better price power believ strategi drive higher
growth largest peer also dilut impact clinic lab headwind
base burlington nc laboratori corpor america hold second largest revenu
clinic refer laboratori compani largest clinic trial central lab second largest preclin
contract research organ cro seventh largest clinic cro compani oper two
segment labcorp diagnost lcd covanc drug develop cdd lcd conduct wide rang
clinic diagnost test routin esoter primarili cdd serv pharmaceut
compani outsourc drug develop servic includ preclin clinic central
laboratori corpor america
